A Trial of Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy for Patients with Multiple Myeloma
The purpose of this study is to compare three-year progression free survival of people with multiple myeloma between three treatment arms: 1)Tandem autologous transplants plus maintenance therapy 2)Single autologous transplant plus consolidation therapy with lenalidomide, bortezomib, and dexamethasone, followed by maintenence therapy 3)Single autologous transplant plus maintenance therapy. All patients will undergo first autologous SC transplant with high dose melphalan given on day -2. Lenalidomide will be used as the maintenance therapy for three years in all three arms, starting at 10mg/day dosage for first 3 months, and increasing to 15mg/day thereafter.
*Eligible patients are ≤70 years old *Karnofsky of ≥70% *Symptomatic MM requiring treatment *Have received at least two cycles of systemic therapy *Are within two months of initiation of the initial therapy *Patients must have available an autograph of ≥ 4x 10^6 CD34+ cells/kg of patient weight.
18 - 70
Healthy Volunteers Needed
Duration of Participation
Up to 4 years
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org
National Institutes of Health/NHLBI,NCI